|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-6.58/-1.41
|
企業價值
4.40B
|
資產負債 |
每股賬面淨值
1.92
|
現金流量 |
現金流量率
--
|
損益表 |
收益
270.60M
|
每股收益
4.61
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/24 12:23 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |